At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 105 enrolled
Drug / intervention
LAM group +1 moredrug
Likely dose
LAM group 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase III Study of Adefovir Dipivoxil Tablets in Patients With Compensated Chronic Hepatitis B -Comparative Study Against Lamivudine-
In Brief
A Phase 3 clinical trial evaluating LAM group and ADV group for Chronic Hepatitis B. Completed, enrolled 105 participants.
Detailed Summary
This study is designed to compare the efficacy and safety of adefovir dipivoxil 10 mg with lamivudine 100 mg in Japanese patients with compensated chronic hepatitis B over 52-week periods.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis B
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2006
First PostedApr 2006
Primary CompletionJan 2008
TodayJul 2026
First PostedApr 21, 2006
Enrollment StartJan 1, 2006
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 20.2 years ago
Interventions
LAM groupdrug
Subjects took one LAM 100mg tablet orally once daily and one ADV placebo tablet orally once daily.
ADV groupdrug
Subjects took one ADV 10mg tablet orally once daily and one LAM placebo tablet orally once daily.